'Huge potential opportunity' for Edmonton pharmaceutical industry as FDA approves Aurinia lupus drug
By
Hiba Kamal-Choufi
in the
Health Innovation Roundup
A made-in-Edmonton drug that can treat lupus nephritis received the first U.S. Food and Drug Administration (FDA) approval as an oral therapy for the disease, Victoria-based Aurinia Pharmaceuticals announced in a statement on Jan. 22.
Applied Pharmaceutical Innovation CEO Andrew MacIsaac said the FDA approval is a huge success story for pharmaceutical companies in the region.
"I'd liken it to the same level as getting a Nobel Prize," MacIsaac told Taproot Edmonton. "This is a strong validation of the work we do and a huge potential opportunity for the future out of Edmonton."
According to MacIsaac, it is very rare for novel drugs to get FDA approval.
"Within the lifespan of the FDA, there's been about 2,000 drugs approved. We are talking about drugs that have never been in humans before going on to the market," he said. "Within Edmonton, only a few drugs have ever ended up on the market out of all our commercialization efforts."